Levosimendan Versus Dobutamine in Shock Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00093301 |
Recruitment Status : Unknown
Verified October 2004 by Wentworth Area Health Services.
Recruitment status was: Recruiting
First Posted : October 7, 2004
Last Update Posted : June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiogenic Shock Septic Shock | Drug: Levosimendan Drug: Dobutamine | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study |
Study Start Date : | October 2004 |
Study Completion Date : | April 2006 |
- Resolution of shock state
- Change in cardiac functions

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 0 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Reduced left ventricular systolic function
- Hypotension
- Anuria or oligouria
Exclusion Criteria:
- Less than 18 years old
- Pregnant
- Uncorrected valvular stenosis
- Hypertrophic obstructive cardiomyopathy (HOCM)
- Third degree AV block

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00093301
Australia, New South Wales | |
Intensive Care Unit, Nepean Hospital | Recruiting |
Penrith, New South Wales, Australia, 2750 | |
Contact: Anthony S McLean, MD +61-2-47342490 mcleana@wahs.nsw.gov.au | |
Contact: Stephen J Huang, PhD +61-247342320 huangs@wahs.nsw.gov.au | |
Principal Investigator: Anthony S McLean, MD | |
Sub-Investigator: Stephen J Huang, PhD | |
Sub-Investigator: Ian Seppelt, MD | |
Sub-Investigator: Marek Nalos, MD |
ClinicalTrials.gov Identifier: | NCT00093301 |
Other Study ID Numbers: |
03/007 |
First Posted: | October 7, 2004 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | October 2004 |
Shock Levosimendan Inotropes |
Dobutamine Heart failure Sepsis |
Shock, Cardiogenic Shock Pathologic Processes Myocardial Infarction Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Infarction Ischemia Necrosis Simendan Dobutamine Cardiotonic Agents Vasodilator Agents |
Phosphodiesterase 3 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Adrenergic beta-1 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents |